Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company focused on antiviral and oncology therapeutics, with its strongest political signal being $37.4M in annual doctor payments (2024) and $23,500 in campaign donations to members of health and tax committees.
BusinessWhat GILD does
Gilead Sciences develops and commercializes therapeutics for life-threatening diseases, primarily in virology (HIV, hepatitis, COVID-19) and oncology (cell therapy). Revenue is generated through product sales, with significant exposure to government healthcare reimbursement and pricing policies. The company operates globally, with U.S. sales subject to Medicare, Medicaid, and commercial insurance coverage.
12 months past · 3 months futureGILD activity timeline
Lifetime Government AwardsGILD federal contracts
GILD doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding GILD
Politicians Trading GILDMembers of Congress with recent GILD positions
Congressional TradesWho in Congress is trading GILD
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Stock awards & option exercises
Bills Affecting GILDLive legislation impacting this stock
Political ProfileWhere GILD sits in Washington
[object Object]
STRUCTURAL: High regulatory density (85) and government dependence (65) due to pharma sector, with donations ($23,500) targeting key health and tax committees (Energy and Commerce, Finance, Ways and Means). EVIDENTIARY: No insider buys (tier F, 0 buys), no federal contracts, no lobbying spend, weak contribution patterns, but congressional trades show 6 purchases and 5 sales in last 12 months (net 1 purchase, low dollar amounts). Net: Structural exposure high but evidentiary signals mixed.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Drug pricing legislation impacting revenueCongress (multiple committees)"Recent bill_impacts shows 8 pharma bills each with 0.0001 impact_ratio, estimated revenue impacts up to $22.5M per bill"
-
Increased scrutiny of physician paymentsHHS/CMS (Open Payments)"get_political_influence.doctor_payments shows $37.4M in 2024 payments to 118,085 physicians, potential regulatory risk"
Regulatory opportunities
-
Coverage and reimbursement for cell therapiesCMS (Medicare)"Doctor payments for Kite Pharma (subsidiary) oncology products, $1.26M in 2024, indicating clinical adoption"
-
Patent protection and market exclusivity for antiviralsFDA, USPTO"No direct field, but sector exposure implies regulatory opportunities in drug approval pathways"
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for GILD — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades GILD
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord